Shanghai Henlius Biotech, Inc.
2696
Kedudukan dalam Saham
#4222
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Harga Saham
$6.89
Modal Pasaran
$3.76B
Perubahan (1 hari)
2.96%
Perubahan (1 tahun)
-27.06%
Negara
CN
Perdagangan Shanghai Henlius Biotech, Inc. (2696)
Kategori
Healthcare
Bilangan saham terbitan bagi Shanghai Henlius Biotech, Inc. (2696)
Bilangan saham terbitan setakat June 2026: 544.86M
Menurut laporan kewangan terkini dan harga saham Shanghai Henlius Biotech, Inc., bilangan saham terbitan semasa ialah 544.86M. Pada akhir December 2023, syarikat mempunyai 546.02M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Shanghai Henlius Biotech, Inc. (2696) dari 2017 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 544.86M | 0.25% |
| 2024 | 543.50M | -0.46% |
| 2023 | 546.02M | 0.74% |
| 2022 | 542.02M | 0.80% |
| 2021 | 537.73M | 1.75% |
| 2020 | 528.48M | 6.30% |
| 2019 | 497.16M | -4.53% |
| 2018 | 520.74M | -3.41% |
| 2017 | 539.13M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | -53.40% |
US
|
|
| 396.00M | -27.32% |
US
|
|
| 478.91M | -12.10% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -88.59% |
NL
|
